Authors

Jean Lopategui, MD

Latest:

Dr. Lopategui on the Evolution of Targeted Therapies in NSCLC

Jean Lopategui, MD, discusses the evolution of targeted therapies in non–small cell lung cancer.

Jean-Pascal Machiels, MD

Latest:

Dr. Machiels on Challenges and Ongoing Trials in Head and Neck Cancer

Jean-Pascal Machiels, MD, head of the Department of Medical Oncology, Cliniques Universitaires Sain-Luc, discusses challenges still facing the field of head and neck cancer and ongoing trials with a goal to improve patient outcomes.

Jean Weigert, MD

Latest:

Dr. Weigert on Cancer Screening for Women With Dense Breasts

Jean Wright, MD

Latest:

Dr. Wright on the Benefit of Moderate Hypofractionation in Early-Stage Breast Cancer

Jean Wright, MD, discusses the benefit of moderate hypofractionation in patients for adjuvant radiotherapy in patients with early-stage breast cancer.

Jean-Yves Blay, MD, PhD

Latest:

Dr. Blay on Treatment Considerations in Soft Tissue Sarcomas

Jean-Yves Blay, MD, discusses treatment considerations in patients with soft tissue sarcomas.

Jean-Yves Blay, MD, PhD, Centre Leon Berard

Jeanine Stiles

Latest:

Jeanine Stiles on the Importance of Supportive Care for Patients With Cancer

Jeanine Stiles, chief administrative officer, associate director for administration, UC Davis Comprehensive Cancer Center, discusses the importance of supportive care for patients with cancer.

Jeanne M. Palmer, MD

Latest:

Myeloproliferative Neoplasm Management: Future Directions in Care

Closing out their discussion on myeloproliferative neoplasms, key opinion leaders share excitement for future evolutions in the treatment paradigm.

Jeannette Y. Wick, RPh, MBA

Latest:

New Therapies for Prostate Cancer: The Practicalities

Now, with four new agents approved in the last two years and two promising agents in the pipeline, therapy selection and potential outcomes are changing.

Jeannie Chern, MD

Latest:

Dr. Chern on Challenges Regarding Germline Testing in Ovarian Cancer

Jeannie Chern, MD, discusses challenges with germline molecular testing for patients with ovarian cancer.

Jeannine Brant, PhD, APRN, AOCN

Latest:

Jeannine Brant on the Benefits of Patient-Reported Outcomes

Jeannine Brant, PhD, Billings Clinic, discusses the benefits of patient-reported outcomes in cancer care.

Jed A. Katzel, MD

Latest:

Dr. Katzel on Differences in Therapy Between Men and Women With Head and Neck Cancer

Jed A. Katzel, MD, Hematology, Kaiser Permanente Santa Clara Medical Center, discusses differences in treatment decisions between men and women with head and neck cancer.

Jed Katzel, MD

Latest:

Dr. Katzel on Women Being Undertreated for Head and Neck Cancer

Jed Katzel, MD, Hematology, Kaiser Permanente Santa Clara Medical Center, discusses research presented at the 2018 ASCO Annual Meeting, which evaluated whether women are undertreated for head and neck cancer.

Jedd D. Wolchok, MD, PhD

Latest:

Dr. Wolchok on Weighing Risk and Benefit of Nivolumab/Ipilimumab Combo in Melanoma

Jedd D. Wolchok, MD, PhD, chief, Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, discusses weighing the overall survival (OS) benefit with the increased risk of toxicities seen with the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in treatment-naïve patients with advanced melanoma.

Jeff Geschwind, MD

Latest:

Dr. Geschwind on Locoregional Therapy for Patients With Liver Cancer

Jeff Geschwind, MD, professor and chairman, Radiology and Biomedical Imaging, Yale Cancer Center, discusses locoregional treatment options for patients with hepatocellular carcinoma (HCC).

Jeff Geschwind, MD, Johns Hopkins

Jeff Michalski, MD

Latest:

Dr. Michalski on Minimizing Long-Term Consequences of Radiation

Jeff Michalski, MD, professor, vice chair of Radiation Oncology, Washington University School of Medicine, Siteman Cancer Center explains the importance of minimizing the long-term consequences of radiation.

Jeff P. Sharman, MD

Latest:

Dr. Sharman on the Challenges of Adjusting Treatment Based on MRD Status in CLL

Jeff P. Sharman, MD, discusses the challenges of adjusting treatments based on minimal residual disease status in high-risk chronic lymphocytic leukemia.

Jeff Prescott, PharmD

Latest:

TechSectors: Mobile/Wireless: iPhone 3G, the First 30 Days

Last year, I promised myself not to accept waiting in line for the iPhone "classic" and was fortunate enough to sneak into an Apple store late one night to purchase one without any hassles.

Jeff Sharman, MD

Latest:

Dr. Sharman on 5-Year Data From the Elevate CLL TN Trial in CLL

Jeff Sharman, MD, discusses 5-year follow-up data from the phase 3 Elevate CLL TN trial in treatment-naïve patients with chronic lymphocytic leukemia.